Opinion|Videos|February 28, 2025
ASCO 2025: Updates From NIAGRA Trial
Panelists discuss how incorporating both neoadjuvant and adjuvant treatment approaches into clinical trial designs has shown promising improvements in event-free survival outcomes across multiple cancer types.
Advertisement
Advertisement
Related to this article
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.
New Name, Same Connection to Care
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
2
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5